Danaher Corporation (NYSE:DHR) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of Danaher Corporation (NYSE:DHR) have received an average recommendation of “Moderate Buy” from the twenty-five analysts that are presently covering the stock, MarketBeat Ratings reports. Five equities research analysts have rated the stock with a hold recommendation, nineteen have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month price objective among brokerages that have issued a report on the stock in the last year is $228.9130.

Several equities analysts recently issued reports on the company. Citigroup began coverage on Danaher in a research report on Tuesday, May 26th. They issued a “buy” rating and a $230.00 target price on the stock. Royal Bank Of Canada boosted their price target on Danaher from $200.00 to $215.00 and gave the company an “outperform” rating in a research note on Wednesday. Rothschild & Co Redburn set a $205.00 price objective on Danaher in a report on Friday, April 17th. Argus reduced their price objective on Danaher from $265.00 to $230.00 and set a “buy” rating for the company in a research note on Friday, April 24th. Finally, Wells Fargo & Company decreased their target price on Danaher from $212.00 to $195.00 and set an “equal weight” rating for the company in a report on Wednesday.

Danaher Trading Up 0.2%

Shares of Danaher stock opened at $191.87 on Monday. The firm’s 50 day simple moving average is $185.64 and its two-hundred day simple moving average is $196.76. The firm has a market capitalization of $134.88 billion, a price-to-earnings ratio of 34.08, a PEG ratio of 2.38 and a beta of 0.79. Danaher has a 12-month low of $160.93 and a 12-month high of $242.80. The company has a current ratio of 1.65, a quick ratio of 1.25 and a debt-to-equity ratio of 0.48.

Danaher (NYSE:DHR) last posted its quarterly earnings data on Tuesday, July 21st. The conglomerate reported $1.94 EPS for the quarter, topping the consensus estimate of $1.85 by $0.09. The business had revenue of $6.26 billion during the quarter, compared to the consensus estimate of $6.12 billion. Danaher had a net margin of 15.95% and a return on equity of 11.04%. The business’s revenue for the quarter was up 5.5% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.77 earnings per share. Analysts predict that Danaher will post 8.53 EPS for the current year.

Danaher Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, July 31st. Investors of record on Friday, June 26th will be issued a $0.40 dividend. This represents a $1.60 annualized dividend and a yield of 0.8%. The ex-dividend date is Friday, June 26th. Danaher’s dividend payout ratio is 28.42%.

Danaher News Roundup

Here are the key news stories impacting Danaher this week:

• Positive Sentiment: J.P. Morgan reiterated a Buy rating on Danaher, which may help support investor confidence after the post-earnings pullback. J.P. Morgan Keeps Their Buy Rating on Danaher (DHR)
• Positive Sentiment: Several articles argue Danaher’s recent slump looks like an overreaction and could be a buying opportunity, suggesting the stock may recover if investors refocus on its long-term fundamentals. Here’s Why the Slump in Danaher Stock This Week Looks Like a Buying Opportunity
• Positive Sentiment: Danaher’s quarterly results beat estimates, with EPS of $1.94 versus $1.85 expected and revenue of $6.27 billion above forecasts, which supports the case that core business performance remains solid. The ‘Standout Performance’ That Could Save Thermo Fisher, Danaher And Others
• Neutral Sentiment: Billionaire investor Dan Loeb reduced his Danaher stake in Q1 2026, adding to sentiment pressure around life sciences tools stocks, though it does not change Danaher’s operating results. Billionaire Investor Dumps Thermo Fisher, Cuts Danaher As He Pares Life Sciences Tools Bets
• Neutral Sentiment: Danaher saw unusually heavy put option activity, signaling traders are hedging against more downside in the near term. Don’t Quit on Danaher Stock After Horrific Earnings Reaction

Institutional Trading of Danaher

Several institutional investors and hedge funds have recently bought and sold shares of the business. Norges Bank acquired a new stake in shares of Danaher in the fourth quarter worth $2,177,106,000. Viking Global Investors LP lifted its position in Danaher by 543.9% during the second quarter. Viking Global Investors LP now owns 2,907,515 shares of the conglomerate’s stock valued at $574,351,000 after purchasing an additional 2,455,994 shares during the period. Massachusetts Financial Services Co. MA boosted its holdings in Danaher by 104.7% in the fourth quarter. Massachusetts Financial Services Co. MA now owns 4,333,056 shares of the conglomerate’s stock valued at $991,923,000 after purchasing an additional 2,216,789 shares during the last quarter. Wellington Management Group LLP grew its position in Danaher by 11.2% during the 4th quarter. Wellington Management Group LLP now owns 15,076,796 shares of the conglomerate’s stock worth $3,451,380,000 after purchasing an additional 1,517,904 shares during the period. Finally, Capital International Investors grew its position in Danaher by 8.9% during the 4th quarter. Capital International Investors now owns 18,246,008 shares of the conglomerate’s stock worth $4,177,386,000 after purchasing an additional 1,487,768 shares during the period. 79.05% of the stock is currently owned by institutional investors and hedge funds.

About Danaher

Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.